{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:21:29Z","timestamp":1790688089055,"version":"4.1.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["SOP-159230"],"award-info":[{"award-number":["SOP-159230"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Advances"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omta.2026.201766","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T15:17:18Z","timestamp":1779722238000},"page":"201766","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Preclinical efficacy of a gene therapy for CHKB-mediated muscular dystrophy"],"prefix":"10.1016","volume":"34","author":[{"given":"Mahtab","family":"Tavasoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam","family":"Alkandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Dorighello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Devitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Hagerty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Damsker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0822-5776","authenticated-orcid":false,"given":"Christopher R.","family":"McMaster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omta.2026.201766_bib1","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/s10038-021-00913-1","article-title":"Megaconial congenital muscular dystrophy secondary to novel CHKB mutations resemble atypical Rett syndrome","volume":"66","author":"Bardhan","year":"2021","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.omta.2026.201766_bib2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/mus.24446","article-title":"Novel CHKB mutation expands the megaconial muscular dystrophy phenotype","volume":"51","author":"Cabrera-Serrano","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.omta.2026.201766_bib3","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.braindev.2015.05.008","article-title":"Congenital neurogenic muscular atrophy in megaconial myopathy due to a mutation in CHKB gene","volume":"38","author":"Castro-Gago","year":"2016","journal-title":"Brain Dev."},{"key":"10.1016\/j.omta.2026.201766_bib4","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.ejpn.2014.06.005","article-title":"Exome sequencing identifies a CHKB mutation in Spanish patient with megaconial congenital muscular dystrophy and mtDNA depletion","volume":"18","author":"Castro-Gago","year":"2014","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.omta.2026.201766_bib5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.nmd.2019.10.009","article-title":"Megaconial congenital muscular dystrophy: Same novel homozygous mutation in CHKB gene in two unrelated Chinese patients","volume":"30","author":"Chan","year":"2020","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omta.2026.201766_bib6","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s10048-025-00851-6","article-title":"Alternative splicing events of three rare variants in CHKB gene causing megaconial congenital dystrophy","volume":"26","author":"Cotrina-Vinagre","year":"2025","journal-title":"Neurogenetics"},{"key":"10.1016\/j.omta.2026.201766_bib7","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/mus.25183","article-title":"A milder phenotype of megaconial congenital muscular dystrophy due to a novel CHKB mutation","volume":"54","author":"De Fuenmayor-Fernandez De La Hoz","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.omta.2026.201766_bib8","doi-asserted-by":"crossref","first-page":"480","DOI":"10.4103\/aian.aian_999_24","article-title":"Novel CHKB Mutation Causing Megaconial Congenital Muscular Dystrophy: A Case Report from India","volume":"28","author":"Gowda","year":"2025","journal-title":"Ann. Indian Acad. Neurol."},{"key":"10.1016\/j.omta.2026.201766_bib9","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/archneurol.2011.2333","article-title":"Congenital megaconial myopathy due to a novel defect in the choline kinase Beta gene","volume":"69","author":"Gutierrez Rios","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.omta.2026.201766_bib10","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s10545-015-9856-2","article-title":"Clinical characteristics of megaconial congenital muscular dystrophy due to choline kinase beta gene defects in a series of 15 patients","volume":"38","author":"Haliloglu","year":"2015","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.omta.2026.201766_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1469237","article-title":"A rare homozygous variant of CHKB induced severe cardiomyopathy and a cardiac conduction disorder: a case report","volume":"11","author":"Jing","year":"2024","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.omta.2026.201766_bib12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13395-022-00306-8","article-title":"Megaconial congenital muscular dystrophy due to novel CHKB variants: a case report and literature review","volume":"12","author":"Magri","year":"2022","journal-title":"Skeletal Muscle"},{"key":"10.1016\/j.omta.2026.201766_bib13","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/WCO.0b013e328364c82d","article-title":"Megaconial congenital muscular dystrophy due to loss-of-function mutations in choline kinase beta","volume":"26","author":"Mitsuhashi","year":"2013","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.omta.2026.201766_bib14","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/jhg.2015.20","article-title":"New splicing mutation in the choline kinase beta (CHKB) gene causing a muscular dystrophy detected by whole-exome sequencing","volume":"60","author":"Oliveira","year":"2015","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.omta.2026.201766_bib15","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.nmd.2013.04.002","article-title":"Muscular dystrophy with large mitochondria associated with mutations in the CHKB gene in three British patients: extending the clinical and pathological phenotype","volume":"23","author":"Quinlivan","year":"2013","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omta.2026.201766_bib16","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.nmd.2023.06.006","article-title":"Megaconial congenital muscular dystrophy due to CHKB gene variants, the first report of thirteen Iranian patients","volume":"33","author":"Zemorshidi","year":"2023","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omta.2026.201766_bib17","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1016\/S0140-6736(19)32910-1","article-title":"Muscular dystrophies","volume":"394","author":"Mercuri","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.omta.2026.201766_bib18","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/s41580-021-00389-z","article-title":"Molecular and cellular basis of genetically inherited skeletal muscle disorders","volume":"22","author":"Dowling","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.omta.2026.201766_bib19","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.nmd.2015.11.002","article-title":"Proximal myopathy with focal depletion of mitochondria and megaconial congenital muscular dystrophy are allelic conditions caused by mutations in CHKB","volume":"26","author":"Brady","year":"2016","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omta.2026.201766_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-97294-4","article-title":"Reduced mitochondrial fission and impaired energy metabolism in human primary skeletal muscle cells of Megaconial Congenital Muscular Dystrophy","volume":"11","author":"Aksu-Menges","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omta.2026.201766_bib21","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.mito.2019.04.002","article-title":"Alteration of mitochondrial membrane inner potential in three Italian patients with megaconial congenital muscular dystrophy carrying new mutations in CHKB gene","volume":"47","author":"Marchet","year":"2019","journal-title":"Mitochondrion"},{"key":"10.1016\/j.omta.2026.201766_bib22","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1093\/brain\/awac074","article-title":"Bi-allelic variants in CHKA cause a neurodevelopmental disorder with epilepsy and microcephaly","volume":"145","author":"Kl\u00f6ckner","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.omta.2026.201766_bib23","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/1873-3468.12919","article-title":"From yeast to humans - roles of the Kennedy pathway for phosphatidylcholine synthesis","volume":"592","author":"McMaster","year":"2018","journal-title":"FEBS Lett."},{"key":"10.1016\/j.omta.2026.201766_bib24","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1074\/jbc.M512578200","article-title":"A rostrocaudal muscular dystrophy caused by a defect in choline kinase beta, the first enzyme in phosphatidylcholine biosynthesis","volume":"281","author":"Sher","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omta.2026.201766_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100213","article-title":"Choline kinase inhibition promotes ER-phagy","volume":"63","author":"Tavasoli","year":"2022","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.omta.2026.201766_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.101716","article-title":"A mouse model of inherited choline kinase beta-deficiency presents with specific cardiac abnormalities and a predisposition to arrhythmia","volume":"298","author":"Tavasoli","year":"2022","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omta.2026.201766_bib27","doi-asserted-by":"crossref","first-page":"17877","DOI":"10.1074\/jbc.REV120.013529","article-title":"Genetic diseases of the Kennedy pathways for membrane synthesis","volume":"295","author":"Tavasoli","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omta.2026.201766_bib28","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1038\/s41467-022-29270-z","article-title":"Mechanism of action and therapeutic route for a muscular dystrophy caused by a genetic defect in lipid metabolism","volume":"13","author":"Tavasoli","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omta.2026.201766_bib29","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1091\/mbc.E15-03-0159","article-title":"Nuclear-localized CTP:phosphocholine cytidylyltransferase alpha regulates phosphatidylcholine synthesis required for lipid droplet biogenesis","volume":"26","author":"Aitchison","year":"2015","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.omta.2026.201766_bib30","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.devcel.2018.05.001","article-title":"CCTalpha Commands Phospholipid Homeostasis from the Nucleus","volume":"45","author":"Cornell","year":"2018","journal-title":"Dev. Cell"},{"key":"10.1016\/j.omta.2026.201766_bib31","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1016\/j.jmb.2020.03.024","article-title":"Membrane Lipids Assist Catalysis by CTP: Phosphocholine Cytidylyltransferase","volume":"432","author":"Cornell","year":"2020","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.omta.2026.201766_bib32","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.plipres.2015.07.001","article-title":"CTP:phosphocholine cytidylyltransferase: Function, regulation, and structure of an amphitropic enzyme required for membrane biogenesis","volume":"59","author":"Cornell","year":"2015","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.omta.2026.201766_bib33","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1074\/jbc.RA118.006457","article-title":"Disease-linked mutations in the phosphatidylcholine regulatory enzyme CCTalpha impair enzymatic activity and fold stability","volume":"294","author":"Cornell","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omta.2026.201766_bib34","doi-asserted-by":"crossref","first-page":"ar33","DOI":"10.1091\/mbc.E23-09-0354","article-title":"Lipid- and phospho-regulation of CTP:Phosphocholine Cytidylyltransferase alpha association with nuclear lipid droplets","volume":"35","author":"Foster","year":"2024","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.omta.2026.201766_bib35","doi-asserted-by":"crossref","first-page":"33535","DOI":"10.1074\/jbc.M109.053363","article-title":"Crystal structure of a mammalian CTP: phosphocholine cytidylyltransferase catalytic domain reveals novel active site residues within a highly conserved nucleotidyltransferase fold","volume":"284","author":"Lee","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omta.2026.201766_bib36","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1194\/jlr.M087635","article-title":"Phosphatidylcholine synthesis regulates triglyceride storage and chylomicron secretion by Caco2 cells","volume":"59","author":"Lee","year":"2018","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.omta.2026.201766_bib37","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1074\/jbc.M113.526970","article-title":"Structural basis for autoinhibition of CTP:phosphocholine cytidylyltransferase (CCT), the regulatory enzyme in phosphatidylcholine synthesis, by its membrane-binding amphipathic helix","volume":"289","author":"Lee","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omta.2026.201766_bib38","doi-asserted-by":"crossref","first-page":"7070","DOI":"10.1074\/jbc.RA118.002053","article-title":"An auto-inhibitory helix in CTP:phosphocholine cytidylyltransferase hijacks the catalytic residue and constrains a pliable, domain-bridging helix pair","volume":"293","author":"Ramezanpour","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omta.2026.201766_bib39","doi-asserted-by":"crossref","first-page":"7085","DOI":"10.1074\/jbc.H118.002882","article-title":"How CCTalpha puts a leash on phospholipid synthesis","volume":"293","author":"Ridgway","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omta.2026.201766_bib40","doi-asserted-by":"crossref","first-page":"28137","DOI":"10.1074\/jbc.M802595200","article-title":"Contribution of each membrane binding domain of the CTP:phosphocholine cytidylyltransferase-alpha dimer to its activation, membrane binding, and membrane cross-bridging","volume":"283","author":"Taneva","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omta.2026.201766_bib41","doi-asserted-by":"crossref","first-page":"17169","DOI":"10.1074\/jbc.X117.815100","article-title":"From masochistic enzymology to mechanistic physiology and disease","volume":"292","author":"Vance","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omta.2026.201766_bib42","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1091\/mbc.E20-01-0014","article-title":"Differential dephosphorylation of CTP:phosphocholine cytidylyltransferase upon translocation to nuclear membranes and lipid droplets","volume":"31","author":"Yue","year":"2020","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.omta.2026.201766_bib43","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/iub.337","article-title":"The Kennedy pathway--De novo synthesis of phosphatidylethanolamine and phosphatidylcholine","volume":"62","author":"Gibellini","year":"2010","journal-title":"IUBMB Life"},{"key":"10.1016\/j.omta.2026.201766_bib44","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1042\/bj3390291","article-title":"Cloning and expression of a human choline\/ethanolaminephosphotransferase: synthesis of phosphatidylcholine and phosphatidylethanolamine","volume":"339","author":"Henneberry","year":"1999","journal-title":"Biochem. J."},{"key":"10.1016\/j.omta.2026.201766_bib45","doi-asserted-by":"crossref","first-page":"29808","DOI":"10.1074\/jbc.M005786200","article-title":"Cloning, genomic organization, and characterization of a human cholinephosphotransferase","volume":"275","author":"Henneberry","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omta.2026.201766_bib46","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1091\/mbc.01-11-0540","article-title":"The major sites of cellular phospholipid synthesis and molecular determinants of Fatty Acid and lipid head group specificity","volume":"13","author":"Henneberry","year":"2002","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.omta.2026.201766_bib47","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1074\/jbc.M114.567966","article-title":"Choline kinase beta mutant mice exhibit reduced phosphocholine, elevated osteoclast activity, and low bone mass","volume":"290","author":"Kular","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omta.2026.201766_bib48","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1093\/hmg\/ddz068","article-title":"Functional rescue in a mouse model of congenital muscular dystrophy with megaconial myopathy","volume":"28","author":"Sayed-Zahid","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omta.2026.201766_bib49","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.bbalip.2009.02.006","article-title":"Understanding the muscular dystrophy caused by deletion of choline kinase beta in mice","volume":"1791","author":"Wu","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.omta.2026.201766_bib50","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.bbalip.2009.12.003","article-title":"Differential expression of choline kinase isoforms in skeletal muscle explains the phenotypic variability in the rostrocaudal muscular dystrophy mouse","volume":"1801","author":"Wu","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.omta.2026.201766_bib51","doi-asserted-by":"crossref","first-page":"e202301956","DOI":"10.26508\/lsa.202301956","article-title":"Defects in integrin complex formation promote CHKB-mediated muscular dystrophy","volume":"7","author":"Tavasoli","year":"2024","journal-title":"Life Sci. Alliance"},{"key":"10.1016\/j.omta.2026.201766_bib52","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bbalip.2004.12.008","article-title":"Regulatory enzymes of phosphatidylcholine biosynthesis: a personal perspective","volume":"1733","author":"Kent","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.omta.2026.201766_bib53","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0969-2126(03)00094-7","article-title":"The crystal structure of choline kinase reveals a eukaryotic protein kinase fold","volume":"11","author":"Peisach","year":"2003","journal-title":"Structure"},{"key":"10.1016\/j.omta.2026.201766_bib54","doi-asserted-by":"crossref","first-page":"5316","DOI":"10.1016\/j.ymthe.2025.09.049","article-title":"Overcoming barriers to commercially pre-viable gene and cell therapies for rare and ultra-rare diseases","volume":"33","author":"Barrett","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201766_bib55","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1016\/j.ymthe.2025.03.065","article-title":"The road toward AAV-mediated gene therapy of Duchenne muscular dystrophy","volume":"33","author":"Bengtsson","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201766_bib56","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1016\/j.ymthe.2025.04.045","article-title":"Current clinical applications of AAV-mediated gene therapy","volume":"33","author":"Byrne","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201766_bib57","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1089\/hum.2023.29242.ddu","article-title":"Duchenne Muscular Dystrophy Gene Therapy in 2023: Status, Perspective, and Beyond","volume":"34","author":"Duan","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201766_bib58","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1177\/10430342251378524","article-title":"Pre-Existing Anti-Adeno-Associated Virus Immunity in Gene Therapy: Mechanisms, Challenges, and Potential Solutions","volume":"36","author":"Iroanya","year":"2025","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201766_bib59","doi-asserted-by":"crossref","first-page":"7S52","DOI":"10.1016\/S0929-693X(25)00254-4","article-title":"Gene therapy in Duchenne muscular dystrophy","volume":"32","author":"Laugel","year":"2025","journal-title":"Arch. Pediatr."},{"key":"10.1016\/j.omta.2026.201766_bib60","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.omta.2026.201766_bib61","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current Clinical Applications of In Vivo Gene Therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201766_bib62","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201766_bib63","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.ymthe.2025.03.064","article-title":"AAV vector development, back to the future","volume":"33","author":"Suarez-Amaran","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201766_bib64","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ymthe.2005.11.015","article-title":"Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain","volume":"13","author":"Cearley","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201766_bib65","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ymthe.2006.05.009","article-title":"Adeno-associated virus serotypes: vector toolkit for human gene therapy","volume":"14","author":"Wu","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201766_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101628","article-title":"Nonclinical toxicity study duration in AAV gene therapy development: Evidence from industry survey supports adequacy of short-term assessments","volume":"33","author":"Assaf","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201766_bib67","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1743-422X-10-74","article-title":"A survey of ex vivo\/in vitro transduction efficiency of mammalian primary cells and cell lines with Nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype","volume":"10","author":"Ellis","year":"2013","journal-title":"Virol. J."},{"key":"10.1016\/j.omta.2026.201766_bib68","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13395-015-0064-4","article-title":"Differential myofiber-type transduction preference of adeno-associated virus serotypes 6 and 9","volume":"5","author":"Riaz","year":"2015","journal-title":"Skeletal Muscle"},{"key":"10.1016\/j.omta.2026.201766_bib69","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41591-021-01483-7","article-title":"Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue","volume":"27","author":"Thomsen","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.omta.2026.201766_bib70","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1182\/bloodadvances.2021006419","article-title":"Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy","volume":"6","author":"Guillou","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.omta.2026.201766_bib71","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","article-title":"Lethal immunotoxicity in high-dose systemic AAV therapy","volume":"31","author":"Duan","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201766_bib72","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1089\/hum.2022.29216.bfs","article-title":"Novartis Confirms Deaths of Two Patients Treated with Gene Therapy Zolgensma","volume":"33","author":"Philippidis","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omta.2026.201766_bib73","article-title":"Efficacy and safety of onasemnogene abeparvovec in children with spinal muscular atrophy type 1: real-world evidence from 6 infusion centres in the United Kingdom","volume":"37","author":"Gowda","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.omta.2026.201766_bib74","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2174\/0113892029361490250310041259","article-title":"Gene Therapy in Rare Genetic Disorders: Current Progress and Future Perspectives","volume":"26","author":"Khawaja","year":"2025","journal-title":"Curr. Genomics"},{"key":"10.1016\/j.omta.2026.201766_bib75","article-title":"Efficacy and safety of gene therapy with onasemnogene abeparvovec in children with spinal muscular atrophy in the D-A-CH-region: a population-based observational study","volume":"47","author":"Wei\u00df","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.omta.2026.201766_bib76","doi-asserted-by":"crossref","DOI":"10.1111\/ped.70019","article-title":"Evaluation of cardiac function in patients with SMA after treatment with onasemnogene abeparvovec","volume":"67","author":"Horigome","year":"2025","journal-title":"Pediatr. Int."},{"key":"10.1016\/j.omta.2026.201766_bib77","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","article-title":"Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy","volume":"78","author":"Mendell","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.omta.2026.201766_bib78","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Mercuri","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omta.2026.201766_bib79","doi-asserted-by":"crossref","DOI":"10.1172\/JCI193956","article-title":"Open-label phase IV trial evaluating nusinersen after onasemnogene abeparvovec in children with spinal muscular atrophy","volume":"135","author":"Proud","year":"2025","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.omta.2026.201766_bib80","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s13023-025-03715-2","article-title":"Postmarketing adverse events associated with onasemnogene abeparvovec: a real-world pharmacovigilance study","volume":"20","author":"Chen","year":"2025","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.omta.2026.201766_bib81","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0092-8674(87)90504-6","article-title":"Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals","volume":"50","author":"Koenig","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.omta.2026.201766_bib82","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.omta.2026.201766_bib83","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/0092-8674(88)90065-7","article-title":"Duchenne muscular dystrophy: deficiency of dystrophin at the muscle cell surface","volume":"54","author":"Bonilla","year":"1988","journal-title":"Cell"},{"key":"10.1016\/j.omta.2026.201766_bib84","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: the protein product of the Duchenne muscular dystrophy locus","volume":"51","author":"Hoffman","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.omta.2026.201766_bib85","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.44178","article-title":"Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial","volume":"5","author":"Mah","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.omta.2026.201766_bib86","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003222","article-title":"Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study","volume":"17","author":"Smith","year":"2020","journal-title":"PLoS Med."},{"key":"10.1016\/j.omta.2026.201766_bib87","doi-asserted-by":"crossref","first-page":"7S3","DOI":"10.1016\/S0929-693X(25)00246-5","article-title":"Genetics and pathophysiology of Duchenne muscular dystrophy","volume":"32","author":"Amthor","year":"2025","journal-title":"Arch. Pediatr."},{"key":"10.1016\/j.omta.2026.201766_bib88","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/j.bbagen.2014.03.008","article-title":"Choline kinase beta is required for normal endochondral bone formation","volume":"1840","author":"Li","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.omta.2026.201766_bib89","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat. Rev. Genet."}],"container-title":["Molecular Therapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26001011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26001011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:18:14Z","timestamp":1789053494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3117387X26001011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":89,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S3117387X26001011"],"URL":"https:\/\/doi.org\/10.1016\/j.omta.2026.201766","relation":{},"ISSN":["3117-387X"],"issn-type":[{"value":"3117-387X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical efficacy of a gene therapy for CHKB-mediated muscular dystrophy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omta.2026.201766","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201766"}}